Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
EASL, infected, infection, inflammation, Issuer, leverage, oversee, poorer, shifting, template, twelve
Removed:
aggressive, Allogene, Alnylam, ASH, BCMA, Beam, cardiovascular, Caribou, Celgene, cohort, CR, CRISPR, CT, cutoff, cyclophosphamide, cytokine, deducting, diagnose, differentiated, diffuse, discontinue, DL, dosing, durable, edit, employing, encephalopathy, enhanced, evade, evaluable, extremely, flat, fludarabine, Gilead, graft, host, immune, inserting, insignificant, Intellia, killer, leukocyte, lymphodepletion, lymphoma, microglobulin, muscle, myeloma, neurotoxicity, nominated, occurring, ORR, outlined, reducing, scan, stealth, suspected, syndrome, tier, underlying, Verve
Filing tables
Filing exhibits
DTIL similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Precision BioSciences, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 4, 2023 | By: | /s/ John Alexander Kelly | |
John Alexander Kelly | |||
Chief Financial Officer | |||
|
|
| (principal financial officer) |